Department of Surgical Oncology, Unit 1484, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Houston, TX 77030, USA.
J Clin Oncol. 2012 Feb 20;30(6):600-7. doi: 10.1200/JCO.2011.36.4976. Epub 2012 Jan 17.
Prediction of patients at highest risk for ipsilateral breast tumor recurrence (IBTR) after local excision of ductal carcinoma in situ (DCIS) remains a clinical concern. The aim of our study was to evaluate a published nomogram from Memorial Sloan-Kettering Cancer Center to predict for risk of IBTR in patients with DCIS from our institution.
We retrospectively identified 794 patients with a diagnosis of DCIS who had undergone local excision from 1990 through 2007 at the MD Anderson Cancer Center (MDACC). Clinicopathologic factors and the performance of the Memorial Sloan-Kettering Cancer Center nomogram for prediction of IBTR were assessed for 734 patients who had complete data.
There was a marked difference with respect to tumor grade, prevalence of necrosis, initial presentation, final margins, and receipt of endocrine therapy between the two cohorts. The biggest difference was that more patients received radiation in the MDACC cohort (75% at MDACC v 49% at MSKCC; P < .001). Follow-up time in the MDACC cohort was longer than in the MSKCC cohort (median 7.1 years v 5.6 years), and the recurrence rate was lower in the MDACC cohort (7.9% v 11%). The median 5-year probability of recurrence was 5%, and the median 10-year probability of recurrence was 7%. The nomogram for prediction of 5- and 10-year IBTR probabilities demonstrated imperfect calibration and discrimination, with a concordance index of 0.63.
Predictive models for IBTR in patients with DCIS who were treated with local excision are imperfect. Our current ability to accurately predict recurrence on the basis of clinical parameters alone is limited.
预测局部切除导管原位癌(DCIS)后同侧乳房肿瘤复发(IBTR)风险最高的患者仍然是临床关注的问题。我们的研究目的是评估来自纪念斯隆-凯特琳癌症中心的一个发表的列线图,以评估我们机构中 DCIS 患者的 IBTR 风险。
我们回顾性地确定了 1990 年至 2007 年期间在 MD 安德森癌症中心(MDACC)接受局部切除的 794 例 DCIS 患者。对 734 例具有完整数据的患者评估了临床病理因素和 Memorial Sloan-Kettering 癌症中心列线图对 IBTR 预测的性能。
两个队列之间在肿瘤分级、坏死的发生率、首发表现、最终切缘和内分泌治疗的应用方面存在明显差异。最大的差异是 MDACC 队列中有更多的患者接受了放疗(MDACC 组为 75%,MSKCC 组为 49%;P <.001)。MDACC 队列的随访时间长于 MSKCC 队列(中位数 7.1 年对 5.6 年),且 MDACC 队列的复发率较低(7.9%对 11%)。中位 5 年复发率为 5%,中位 10 年复发率为 7%。用于预测 5 年和 10 年 IBTR 概率的列线图显示校准和区分度不理想,一致性指数为 0.63。
用于局部切除治疗的 DCIS 患者的 IBTR 预测模型并不完善。我们目前仅凭临床参数准确预测复发的能力有限。